Search results
Body
Showing 61-70 of 255 results
Saint Luke's cardiologists and surgeons perform the full spectrum of cardiovascular interventions and surgeries.
Dr. Mikhail Kosiborod explains the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with HF and higher diastolic pulmonary artery pressure.
In heart transplant recipients, PCSK9 inhibitors lowered LDL, stabilized coronary intimal hyperplasia and were associated with minimal adverse effects, according to data from the virtual Heart Fail
A study supported by the Saint Luke’s Hospital Foundation and conducted by a U.S.-Egyptian research team has uncovered the earliest documented case of coronary atherosclerosis – a build-up of plaque in the arteries that supply the heart muscle that can result in heart attack – in a princess who died in her early 40’s and lived between 1580 and 1550 B.C.
Saint Luke's Hospital of Kansas City ranked among the top two hospitals in the Kansas City metro, according to U.S. News & World Report's annual ranking of medical centers across the country.
ISCHEMIA trial outcomes found a significant benefit in quality of life and patient experience.
Dr. O'Keefe gives his expertise on fish oil - is it beneficial?
Dapagliflozin improved symptoms and physical limitations in patients with heart failure (HF) with preserved ejection fraction, according to results from the PRESERVED-HF trial.
Dr. Mikhail Kosiborod talks about the additional analysis from the EMPULSE trial presented at the American College of Cardiology congress.
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.